BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S, Hainaut P, Marrero JA, Beretta L. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 2012;55:483-90. [PMID: 21953299 DOI: 10.1002/hep.24703] [Cited by in Crossref: 185] [Cited by in F6Publishing: 184] [Article Influence: 16.8] [Reference Citation Analysis]
Number Citing Articles
1 Liu XN, Cui DN, Li YF, Liu YH, Liu G, Liu L. Multiple “Omics” data-based biomarker screening for hepatocellular carcinoma diagnosis. World J Gastroenterol 2019; 25(30): 4199-4212 [PMID: 31435173 DOI: 10.3748/wjg.v25.i30.4199] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
2 Powers TW, Holst S, Wuhrer M, Mehta AS, Drake RR. Two-Dimensional N-Glycan Distribution Mapping of Hepatocellular Carcinoma Tissues by MALDI-Imaging Mass Spectrometry. Biomolecules 2015;5:2554-72. [PMID: 26501333 DOI: 10.3390/biom5042554] [Cited by in Crossref: 66] [Cited by in F6Publishing: 60] [Article Influence: 9.4] [Reference Citation Analysis]
3 Shlomai A. Targeting late SV40 factor: Is the achilles heel of hepatocarcinogenesis revealed? World J Gastroenterol 2012; 18(46): 6709-6711 [PMID: 23239907 DOI: 10.3748/wjg.v18.i46.6709] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
4 Masuzaki R, Karp SJ, Omata M. New serum markers of hepatocellular carcinoma. Semin Oncol. 2012;39:434-439. [PMID: 22846860 DOI: 10.1053/j.seminoncol.2012.05.009] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 5.0] [Reference Citation Analysis]
5 Khattab M, Fouad M, Ahmed E. Role of biomarkers in the prediction and diagnosis of hepatocellular carcinoma. World J Hepatol 2015; 7(23): 2474-2481 [PMID: 26483869 DOI: 10.4254/wjh.v7.i23.2474] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
6 Zhao H, Chen Q, Alam A, Cui J, Suen KC, Soo AP, Eguchi S, Gu J, Ma D. The role of osteopontin in the progression of solid organ tumour. Cell Death Dis 2018;9:356. [PMID: 29500465 DOI: 10.1038/s41419-018-0391-6] [Cited by in Crossref: 94] [Cited by in F6Publishing: 88] [Article Influence: 23.5] [Reference Citation Analysis]
7 Mao D, Chen H, Tang Y, Li J, Cao Y, Zhao J. Application of Isothermal Nucleic Acid Signal Amplification in the Detection of Hepatocellular Carcinoma-Associated MicroRNA. ChemPlusChem 2019;84:8-17. [DOI: 10.1002/cplu.201800382] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
8 Huang T, Wang J, Cai YD, Yu H, Chou KC. Hepatitis C virus network based classification of hepatocellular cirrhosis and carcinoma. PLoS One 2012;7:e34460. [PMID: 22493692 DOI: 10.1371/journal.pone.0034460] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 3.2] [Reference Citation Analysis]
9 Nassef YE, Shady MM, Galal EM, Hamed MA. Performance of diagnostic biomarkers in predicting liver fibrosis among hepatitis C virus-infected Egyptian children. Mem Inst Oswaldo Cruz 2013;108:887-93. [PMID: 24141960 DOI: 10.1590/0074-0276130139] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
10 Sengupta S, Parikh ND. Biomarker development for hepatocellular carcinoma early detection: Current and future perspectives. Hepat Oncol. 2017;4:111-122. [PMID: 30191058 DOI: 10.2217/hep-2017-0019] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
11 Malov SI, Malov IV, Dvornichenko VV, Rasulov RI, Kuvshinov AG, Marche PN, Decaens T, Macek-Jilkova Z, Yushchuk ND. [Application of alpha-fetoprotein and osteopontin combination for early diagnosis of hepatocellular carcinoma associated with hepatitis C.]. Klin Lab Diagn 2019;64:607-12. [PMID: 31742954 DOI: 10.18821/0869-2084-2019-64-10-607-612] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Lv Y, Wang W, Jia WD, Sun QK, Huang M, Zhou HC, Xia HH, Liu WB, Chen H, Sun SN, Xu GL. High preoparative levels of serum periostin are associated with poor prognosis in patients with hepatocellular carcinoma after hepatectomy. Eur J Surg Oncol 2013;39:1129-35. [PMID: 23916473 DOI: 10.1016/j.ejso.2013.06.023] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
13 Zhu J, Warner E, Parikh ND, Lubman DM. Glycoproteomic markers of hepatocellular carcinoma-mass spectrometry based approaches. Mass Spectrom Rev 2019;38:265-90. [PMID: 30472795 DOI: 10.1002/mas.21583] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
14 Lim TS, Kim DY, Han KH, Kim HS, Shin SH, Jung KS, Kim BK, Kim SU, Park JY, Ahn SH. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients. Scand J Gastroenterol. 2016;51:344-353. [PMID: 26340708 DOI: 10.3109/00365521.2015.1082190] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 5.7] [Reference Citation Analysis]
15 Zhang H, Ding R, Chen D. Value of miR-21 levels as potential biomarkers in the early diagnosis of hepatocellular carcinoma:a meta-analysis. Biomarkers 2021;:1-12. [PMID: 34266326 DOI: 10.1080/1354750X.2021.1955976] [Reference Citation Analysis]
16 Yang G, Zhang S, Gao F, Liu Z, Lu M, Peng S, Zhang T, Zhang F. Osteopontin enhances the expression of HOTAIR in cancer cells via IRF1. Biochim Biophys Acta 2014;1839:837-48. [PMID: 24999034 DOI: 10.1016/j.bbagrm.2014.06.020] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
17 Zhang J, Hao N, Liu W, Lu M, Sun L, Chen N, Wu M, Zhao X, Xing B, Sun W, He F. In-depth proteomic analysis of tissue interstitial fluid for hepatocellular carcinoma serum biomarker discovery. Br J Cancer 2017;117:1676-84. [PMID: 29024941 DOI: 10.1038/bjc.2017.344] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
18 Kimhofer T, Fye H, Taylor-Robinson S, Thursz M, Holmes E. Proteomic and metabonomic biomarkers for hepatocellular carcinoma: a comprehensive review. Br J Cancer. 2015;112:1141-1156. [PMID: 25826224 DOI: 10.1038/bjc.2015.38] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 10.4] [Reference Citation Analysis]
19 Iqbal J, McRae S, Mai T, Banaudha K, Sarkar-Dutta M, Waris G. Role of hepatitis C virus induced osteopontin in epithelial to mesenchymal transition, migration and invasion of hepatocytes. PLoS One 2014;9:e87464. [PMID: 24498111 DOI: 10.1371/journal.pone.0087464] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
20 Abdel-Hafiz SM, Hamdy HE, Khorshed FM, Aboushousha TS, Safwat G, Saber MA, Seleem M, Soliman AH. Evaluation of Osteopontin as a Biomarker in Hepatocellular Carcinomas in Egyptian Patients with Chronic HCV Cirrhosis. Asian Pac J Cancer Prev 2018;19:1021-7. [PMID: 29693976 DOI: 10.22034/APJCP.2018.19.4.1021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Villanueva F, Araya H, Briceño P, Varela N, Stevenson A, Jerez S, Tempio F, Chnaiderman J, Perez C, Villarroel M, Concha E, Khani F, Thaler R, Salazar-Onfray F, Stein GS, van Wijnen AJ, Galindo M. The cancer-related transcription factor RUNX2 modulates expression and secretion of the matricellular protein osteopontin in osteosarcoma cells to promote adhesion to endothelial pulmonary cells and lung metastasis. J Cell Physiol 2019;234:13659-79. [PMID: 30637720 DOI: 10.1002/jcp.28046] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
22 Mocan T, Simão AL, Castro RE, Rodrigues CMP, Słomka A, Wang B, Strassburg C, Wöhler A, Willms AG, Kornek M. Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning? J Clin Med 2020;9:E1541. [PMID: 32443747 DOI: 10.3390/jcm9051541] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
23 Bruha R, Vitek L, Smid V. Osteopontin - A potential biomarker of advanced liver disease. Ann Hepatol 2020;19:344-52. [PMID: 32005637 DOI: 10.1016/j.aohep.2020.01.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
24 Yau WY, Shih HC, Tsai MH, Sheu JC, Chen CH, Chow LP. Autoantibody recognition of an N-terminal epitope of hnRNP L marks the risk for developing HBV-related hepatocellular carcinoma. J Proteomics. 2013;94:346-358. [PMID: 24125732 DOI: 10.1016/j.jprot.2013.10.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
25 da Costa AN, Plymoth A, Santos-Silva D, Ortiz-Cuaran S, Camey S, Guilloreau P, Sangrajrang S, Khuhaprema T, Mendy M, Lesi OA. Osteopontin and latent-TGF β binding-protein 2 as potential diagnostic markers for HBV-related hepatocellular carcinoma. Int J Cancer. 2015;136:172-181. [PMID: 24803312 DOI: 10.1002/ijc.28953] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
26 Nardo AD, Grün NG, Zeyda M, Dumanic M, Oberhuber G, Rivelles E, Helbich TH, Markgraf DF, Roden M, Claudel T, Trauner M, Stulnig TM. Impact of osteopontin on the development of non-alcoholic liver disease and related hepatocellular carcinoma. Liver Int 2020;40:1620-33. [PMID: 32281248 DOI: 10.1111/liv.14464] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
27 Rich N, Singal AG. Hepatocellular carcinoma tumour markers: current role and expectations. Best Pract Res Clin Gastroenterol. 2014;28:843-853. [PMID: 25260312 DOI: 10.1016/j.bpg.2014.07.018] [Cited by in Crossref: 59] [Cited by in F6Publishing: 63] [Article Influence: 7.4] [Reference Citation Analysis]
28 Wu Y, Wu B, Chen R, Zheng Y, Huang Z. High ATF5 expression is a favorable prognostic indicator in patients with hepatocellular carcinoma after hepatectomy. Med Oncol 2014;31. [DOI: 10.1007/s12032-014-0269-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
29 Sun Z, Liu X, Wu D, Gao H, Jiang J, Yang Y, Wu J, Gao Q, Wang J, Jiang Z, Xu Y, Xu X, Li L. Circulating proteomic panels for diagnosis and risk stratification of acute-on-chronic liver failure in patients with viral hepatitis B. Theranostics 2019;9:1200-14. [PMID: 30867825 DOI: 10.7150/thno.31991] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
30 Long J, Zhang L, Wan X, Lin J, Bai Y, Xu W, Xiong J, Zhao H. A four-gene-based prognostic model predicts overall survival in patients with hepatocellular carcinoma. J Cell Mol Med. 2018;22:5928-5938. [PMID: 30247807 DOI: 10.1111/jcmm.13863] [Cited by in Crossref: 56] [Cited by in F6Publishing: 60] [Article Influence: 14.0] [Reference Citation Analysis]
31 Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y, Nakatsura T. Biomarkers for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol 2015; 21(37): 10573-10583 [PMID: 26457017 DOI: 10.3748/wjg.v21.i37.10573] [Cited by in CrossRef: 188] [Cited by in F6Publishing: 182] [Article Influence: 26.9] [Reference Citation Analysis]
32 Dai Y, Han B, Dong L, Zhao J, Cao Y. Recent advances in nanomaterial-enhanced biosensing methods for hepatocellular carcinoma diagnosis. TrAC Trends in Analytical Chemistry 2020;130:115965. [DOI: 10.1016/j.trac.2020.115965] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
33 Tang J, Jiang R, Deng L, Zhang X, Wang K, Sun B. Circulation long non-coding RNAs act as biomarkers for predicting tumorigenesis and metastasis in hepatocellular carcinoma. Oncotarget. 2015;6:4505-4515. [PMID: 25714016 DOI: 10.18632/oncotarget.2934] [Cited by in Crossref: 87] [Cited by in F6Publishing: 89] [Article Influence: 12.4] [Reference Citation Analysis]
34 Page AJ, Cosgrove DC, Philosophe B, Pawlik TM. Hepatocellular Carcinoma. Surgical Oncology Clinics of North America 2014;23:289-311. [DOI: 10.1016/j.soc.2013.10.006] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
35 Du Z, Liu X, Wei X, Luo H, Li P, Shi M, Guo B, Cui Y, Su Z, Zeng J, Si A, Cao P, Zhou G. Quantitative proteomics identifies a plasma multi-protein model for detection of hepatocellular carcinoma. Sci Rep 2020;10:15552. [PMID: 32968147 DOI: 10.1038/s41598-020-72510-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
36 Yin C, Evason KJ, Asahina K, Stainier DY. Hepatic stellate cells in liver development, regeneration, and cancer. J Clin Invest. 2013;123:1902-1910. [PMID: 23635788 DOI: 10.1172/jci66369] [Cited by in Crossref: 363] [Cited by in F6Publishing: 213] [Article Influence: 40.3] [Reference Citation Analysis]
37 Wang W, Wei C. Advances in the early diagnosis of hepatocellular carcinoma. Genes Dis 2020;7:308-19. [PMID: 32884985 DOI: 10.1016/j.gendis.2020.01.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
38 Sun T, Li P, Sun D, Bu Q, Li G. Prognostic value of osteopontin in patients with hepatocellular carcinoma: A systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e12954. [PMID: 30412113 DOI: 10.1097/MD.0000000000012954] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
39 Li J, Chen X, Dai M, Huang S, Chen J, Dai S. Diagnostic accuracy of osteopontin plus alpha-fetoprotein in the hepatocellular carcinoma: A meta-analysis. Clin Res Hepatol Gastroenterol 2017;41:543-53. [PMID: 28291627 DOI: 10.1016/j.clinre.2017.01.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
40 Rychlíková J, Vecka M, Jáchymová M, Macášek J, Hrabák P, Zeman M, Vávrová L, Řoupal J, Krechler T, Ák A. Osteopontin as a discriminating marker for pancreatic cancer and chronic pancreatitis. Cancer Biomark 2016;17:55-65. [PMID: 27314293 DOI: 10.3233/CBM-160617] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
41 Lin YH, Wu MH, Huang YH, Yeh CT, Lin KH. TUG1 Is a Regulator of AFP and Serves as Prognostic Marker in Non-Hepatitis B Non-Hepatitis C Hepatocellular Carcinoma. Cells 2020;9:E262. [PMID: 31973032 DOI: 10.3390/cells9020262] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
42 Mancone C, Ciccosanti F, Montaldo C, Perdomo AB, Piacentini M, Alonzi T, Fimia GM, Tripodi M. Applying proteomic technology to clinical virology. Clin Microbiol Infect 2013;19:23-8. [PMID: 23034105 DOI: 10.1111/1469-0691.12029] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
43 Zhu Y, Gao XM, Yang J, Xu D, Zhang Y, Lu M, Zhang Z, Sheng YY, Li JH, Yu XX, Zheng Y, Dong QZ, Qin LX. C-C chemokine receptor type 1 mediates osteopontin-promoted metastasis in hepatocellular carcinoma. Cancer Sci 2018;109:710-23. [PMID: 29285854 DOI: 10.1111/cas.13487] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
44 Fujiwara N, Friedman SL, Goossens N, Hoshida Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol 2018;68:526-49. [PMID: 28989095 DOI: 10.1016/j.jhep.2017.09.016] [Cited by in Crossref: 198] [Cited by in F6Publishing: 196] [Article Influence: 39.6] [Reference Citation Analysis]
45 Klement JD, Poschel DB, Lu C, Merting AD, Yang D, Redd PS, Liu K. Osteopontin Blockade Immunotherapy Increases Cytotoxic T Lymphocyte Lytic Activity and Suppresses Colon Tumor Progression. Cancers (Basel) 2021;13:1006. [PMID: 33670921 DOI: 10.3390/cancers13051006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
46 Kim KH, Lee SY, Baek JH, Lee SY, Kim JY, Yoo JS. Measuring fucosylated alpha-fetoprotein in hepatocellular carcinoma: A comparison of μTAS and parallel reaction monitoring. Proteomics Clin Appl 2021;15:e2000096. [PMID: 33764665 DOI: 10.1002/prca.202000096] [Reference Citation Analysis]
47 Fouad SA, Mohamed NA, Fawzy MW, Moustafa DA. Plasma Osteopontin Level in Chronic Liver Disease and Hepatocellular Carcinoma. Hepat Mon 2015;15:e30753. [PMID: 26500684 DOI: 10.5812/hepatmon.30753] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
48 Song J, Ge Z, Yang X, Luo Q, Wang C, You H, Ge T, Deng Y, Lin H, Cui Y. Hepatic stellate cells activated by acidic tumor microenvironment promote the metastasis of hepatocellular carcinoma via osteopontin. Cancer Lett. 2015;356:713-720. [PMID: 25449435 DOI: 10.1016/j.canlet.2014.10.021] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 5.0] [Reference Citation Analysis]
49 Gui X, Qiu X, Xie M, Tian Y, Min C, Huang M, Hongyan W, Chen T, Zhang X, Chen J, Cao M, Cai H. Prognostic Value of Serum Osteopontin in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Biomed Res Int 2020;2020:3424208. [PMID: 32104688 DOI: 10.1155/2020/3424208] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
50 Kim KH, Kim JY, Yoo JS. Mass spectrometry analysis of glycoprotein biomarkers in human blood of hepatocellular carcinoma. Expert Review of Proteomics 2019;16:553-68. [DOI: 10.1080/14789450.2019.1626235] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
51 Lee TY, Lin JT, Wu CC, Yu CC, Wu MS, Lee TC, Chen HP, Wu CY. Osteopontin promoter polymorphisms are associated with susceptibility to gastric cancer. J Clin Gastroenterol 2013;47:e55-9. [PMID: 23426449 DOI: 10.1097/MCG.0b013e31827b9325] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
52 Hoseini SS, Cheung NV. Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies. Cancer Lett. 2017;399:44-52. [PMID: 28428075 DOI: 10.1016/j.canlet.2017.04.013] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
53 Lee HJ, Yeon JE, Suh SJ, Lee SJ, Yoon EL, Kang K, Yoo YJ, Kim JH, Seo YS, Yim HJ. Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma. Gut Liver. 2014;8:177-185. [PMID: 24672660 DOI: 10.5009/gnl.2014.8.2.177] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
54 Wen Y, Feng D, Wu H, Liu W, Li H, Wang F, Xia Q, Gao WQ, Kong X. Defective Initiation of Liver Regeneration in Osteopontin-Deficient Mice after Partial Hepatectomy due to Insufficient Activation of IL-6/Stat3 Pathway. Int J Biol Sci 2015;11:1236-47. [PMID: 26327817 DOI: 10.7150/ijbs.12118] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 4.7] [Reference Citation Analysis]
55 Shevde LA, Samant RS. Role of osteopontin in the pathophysiology of cancer. Matrix Biol 2014;37:131-41. [PMID: 24657887 DOI: 10.1016/j.matbio.2014.03.001] [Cited by in Crossref: 140] [Cited by in F6Publishing: 140] [Article Influence: 17.5] [Reference Citation Analysis]
56 Yang B, Li M, Tang W, Liu W, Zhang S, Chen L, Xia J. Dynamic network biomarker indicates pulmonary metastasis at the tipping point of hepatocellular carcinoma. Nat Commun 2018;9:678. [PMID: 29445139 DOI: 10.1038/s41467-018-03024-2] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 16.0] [Reference Citation Analysis]
57 Nabih MI, Aref WM, Fathy MM. Significance of plasma osteopontin in diagnosis of hepatitis C virus-related hepatocellular carcinoma. Arab J Gastroenterol. 2014;15:103-107. [PMID: 25249230 DOI: 10.1016/j.ajg.2014.08.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
58 Adeniji N, Dhanasekaran R. Current and Emerging Tools for Hepatocellular Carcinoma Surveillance. Hepatol Commun 2021. [PMID: 34533885 DOI: 10.1002/hep4.1823] [Reference Citation Analysis]
59 Vongsuvanh R, van der Poorten D, Iseli T, Strasser SI, McCaughan GW, George J. Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma. PLoS One. 2016;11:e0155800. [PMID: 27219517 DOI: 10.1371/journal.pone.0155800] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
60 Chen M, Zheng T, Han S, Zhang L, Bai Y, Fang X, Ding SZ, Yang Y. A preliminary study of plasma cyclase-associated protein 2 as a novel biomarker for early stage and alpha-fetoprotein negative hepatocellular carcinoma patients. Clin Res Hepatol Gastroenterol. 2015;39:215-221. [PMID: 25312778 DOI: 10.1016/j.clinre.2014.08.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
61 Huang C, Zhang C, Sheng J, Wang D, Zhao Y, Qian L, Xie L, Meng Z. Identification and Validation of a Tumor Microenvironment-Related Gene Signature in Hepatocellular Carcinoma Prognosis. Front Genet 2021;12:717319. [PMID: 34899826 DOI: 10.3389/fgene.2021.717319] [Reference Citation Analysis]
62 Wan HG, Xu H, Gu YM, Wang H, Xu W, Zu MH. Comparison osteopontin vs AFP for the diagnosis of HCC: a meta-analysis. Clin Res Hepatol Gastroenterol. 2014;38:706-714. [PMID: 25034355 DOI: 10.1016/j.clinre.2014.06.008] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 5.6] [Reference Citation Analysis]
63 Vacante F, Senesi P, Montesano A, Paini S, Luzi L, Terruzzi I. Metformin Counteracts HCC Progression and Metastasis Enhancing KLF6/p21 Expression and Downregulating the IGF Axis. Int J Endocrinol 2019;2019:7570146. [PMID: 30774659 DOI: 10.1155/2019/7570146] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
64 Lin Q, Guo L, Lin G, Chen Z, Chen T, Lin J, Zhang B, Gu X. Clinical and prognostic significance of OPN and VEGF expression in patients with non-small-cell lung cancer. Cancer Epidemiol 2015;39:539-44. [PMID: 26123318 DOI: 10.1016/j.canep.2015.05.010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
65 Xu G, Yang F, Ding CL, Zhao LJ, Ren H, Zhao P, Wang W, Qi ZT. Small nucleolar RNA 113-1 suppresses tumorigenesis in hepatocellular carcinoma. Mol Cancer. 2014;13:216. [PMID: 25217841 DOI: 10.1186/1476-4598-13-216] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 7.1] [Reference Citation Analysis]
66 Trierweiler C, Hockenjos B, Zatloukal K, Thimme R, Blum HE, Wagner EF, Hasselblatt P. The transcription factor c-JUN/AP-1 promotes HBV-related liver tumorigenesis in mice. Cell Death Differ 2016;23:576-82. [PMID: 26470729 DOI: 10.1038/cdd.2015.121] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
67 Kuang Z, Huang R, Yang Z, Lv Z, Chen X, Xu F, Yi YH, Wu J, Huang RP. Quantitative screening of serum protein biomarkers by reverse phase protein arrays. Oncotarget 2018;9:32624-41. [PMID: 30220970 DOI: 10.18632/oncotarget.25976] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
68 Pelizzaro F, Cardin R, Penzo B, Pinto E, Vitale A, Cillo U, Russo FP, Farinati F. Liquid Biopsy in Hepatocellular Carcinoma: Where Are We Now? Cancers (Basel) 2021;13:2274. [PMID: 34068786 DOI: 10.3390/cancers13092274] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
69 Debes JD, Romagnoli PA, Prieto J, Arrese M, Mattos AZ, Boonstra A, On Behalf Of The Escalon Consortium. Serum Biomarkers for the Prediction of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:1681. [PMID: 33918270 DOI: 10.3390/cancers13071681] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
70 Niu L, Geyer PE, Mann M. Proteomics in the Study of Liver Diseases. In: Krag A, Hansen T, editors. The Human Gut-Liver-Axis in Health and Disease. Cham: Springer International Publishing; 2019. pp. 165-93. [DOI: 10.1007/978-3-319-98890-0_11] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
71 Choi SS, Claridge LC, Jhaveri R, Swiderska-Syn M, Clark P, Suzuki A, Pereira TA, Mi Z, Kuo PC, Guy CD, Pereira FE, Diehl AM, Patel K, Syn WK. Osteopontin is up-regulated in chronic hepatitis C and is associated with cellular permissiveness for hepatitis C virus replication. Clin Sci (Lond) 2014;126:845-55. [PMID: 24438228 DOI: 10.1042/CS20130473] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
72 Song PP, Xia JF, Inagaki Y, Hasegawa K, Sakamoto Y, Kokudo N, Tang W. Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J Gastroenterol 2016; 22(1): 262-274 [PMID: 26755875 DOI: 10.3748/wjg.v22.i1.262] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 61] [Article Influence: 11.5] [Reference Citation Analysis]
73 Sun JY, Xu JM, Yan M, Ye F. Advances in understanding relationship between osteopontin and metastasis and recurrence of hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2013; 21(16): 1498-1504 [DOI: 10.11569/wcjd.v21.i16.1498] [Reference Citation Analysis]
74 Dong Q, Zhu X, Dai C, Zhang X, Gao X, Wei J, Sheng Y, Zheng Y, Yu J, Xie L, Qin Y, Qiao P, Zhou C, Yu X, Jia H, Ren N, Zhou H, Ye Q, Qin L. Osteopontin promotes epithelial-mesenchymal transition of hepatocellular carcinoma through regulating vimentin. Oncotarget 2016;7:12997-3012. [PMID: 26824421 DOI: 10.18632/oncotarget.7016] [Cited by in Crossref: 36] [Cited by in F6Publishing: 45] [Article Influence: 7.2] [Reference Citation Analysis]
75 Attallah AM, El-far M, Omran MM, Abdelrazek MA, Attallah AA, Saeed AM, Farid K. GPC-HCC model: a combination of glybican-3 with other routine parameters improves the diagnostic efficacy in hepatocellular carcinoma. Tumor Biol 2016;37:12571-7. [DOI: 10.1007/s13277-016-5127-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
76 Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. Semin Oncol. 2012;39:410-433. [PMID: 22846859 DOI: 10.1053/j.seminoncol.2012.05.001] [Cited by in Crossref: 103] [Cited by in F6Publishing: 101] [Article Influence: 10.3] [Reference Citation Analysis]
77 Duarte-Salles T, Misra S, Stepien M, Plymoth A, Muller D, Overvad K, Olsen A, Tjønneland A, Baglietto L, Severi G, Boutron-Ruault MC, Turzanski-Fortner R, Kaaks R, Boeing H, Aleksandrova K, Trichopoulou A, Lagiou P, Bamia C, Pala V, Palli D, Mattiello A, Tumino R, Naccarati A, Bueno-de-Mesquita HB, Peeters PH, Weiderpass E, Quirós JR, Agudo A, Sánchez-Cantalejo E, Ardanaz E, Gavrila D, Dorronsoro M, Werner M, Hemmingsson O, Ohlsson B, Sjöberg K, Wareham NJ, Khaw KT, Bradbury KE, Gunter MJ, Cross AJ, Riboli E, Jenab M, Hainaut P, Beretta L. Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population. Cancer Prev Res (Phila) 2016;9:758-65. [PMID: 27339170 DOI: 10.1158/1940-6207.CAPR-15-0434] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
78 Ferrín G, Aguilar-Melero P, Rodríguez-Perálvarez M, Montero-Álvarez JL, de la Mata M. Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility. Hepat Med 2015;7:1-10. [PMID: 25926760 DOI: 10.2147/HMER.S50161] [Cited by in Crossref: 8] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
79 Li L, Qian M, Chen IH, Finkelstein D, Onar-Thomas A, Johnson M, Calabrese C, Bahrami A, López-Terrada DH, Yang JJ, Tao WA, Zhu L. Acquisition of Cholangiocarcinoma Traits during Advanced Hepatocellular Carcinoma Development in Mice. Am J Pathol 2018;188:656-71. [PMID: 29248454 DOI: 10.1016/j.ajpath.2017.11.013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
80 Campion D, Tucci A, Ponzo P, Caviglia GP. Non-invasive biomarkers for the detection of hepatocellular carcinoma. Minerva Biotecnol 2019;31. [DOI: 10.23736/s1120-4826.18.02488-6] [Cited by in Crossref: 13] [Article Influence: 4.3] [Reference Citation Analysis]
81 Cheng J, Wang W, Sun C, Li M, Wang B, Lv Y. Meta-analysis of the prognostic and diagnostic significance of serum/plasma osteopontin in hepatocellular carcinoma. J Clin Gastroenterol 2014;48:806-14. [PMID: 24247813 DOI: 10.1097/MCG.0000000000000018] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
82 Kaleta B. Osteopontin and Transplantation: Where Are We Now? Arch Immunol Ther Exp (Warsz) 2021;69:15. [PMID: 34019147 DOI: 10.1007/s00005-021-00617-6] [Reference Citation Analysis]
83 Moldogazieva NT, Mokhosoev IM, Zavadskiy SP, Terentiev AA. Proteomic Profiling and Artificial Intelligence for Hepatocellular Carcinoma Translational Medicine. Biomedicines 2021;9:159. [PMID: 33562077 DOI: 10.3390/biomedicines9020159] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
84 Briones-Orta MA, Delgado-Coello B, Gutiérrez-Vidal R, Sosa-Garrocho M, Macías-Silva M, Mas-Oliva J. Quantitative Expression of Key Cancer Markers in the AS-30D Hepatocarcinoma Model. Front Oncol 2021;11:670292. [PMID: 34737944 DOI: 10.3389/fonc.2021.670292] [Reference Citation Analysis]
85 Zheng Y, Huang Q, Ding Z, Liu T, Xue C, Sang X, Gu J. Genome-wide DNA methylation analysis identifies candidate epigenetic markers and drivers of hepatocellular carcinoma. Brief Bioinform 2018;19:101-8. [PMID: 27760737 DOI: 10.1093/bib/bbw094] [Cited by in Crossref: 12] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
86 Bergman N, Bergquist J. Recent developments in proteomic methods and disease biomarkers. Analyst 2014;139:3836-51. [PMID: 24975697 DOI: 10.1039/c4an00627e] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
87 Lamerz R. Are Biomarkers Still Helpful in Hepatocellular Carcinoma? Digestion 2013;87:118-20. [DOI: 10.1159/000346282] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
88 Yang L, Rong W, Xiao T, Zhang Y, Xu B, Liu Y, Wang L, Wu F, Qi J, Zhao X. Secretory/releasing proteome-based identification of plasma biomarkers in HBV-associated hepatocellular carcinoma. Sci China Life Sci. 2013;56:638-646. [PMID: 23749381 DOI: 10.1007/s11427-013-4497-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
89 Wang J, Zhang Y, Liu L, Cui Z, Liu X, Wang L, Li Y, Li Q. Combined chemo/photothermal therapy based on mesoporous silica-Au core-shell nanoparticles for hepatocellular carcinoma treatment. Drug Dev Ind Pharm 2019;45:1487-95. [PMID: 31172835 DOI: 10.1080/03639045.2019.1629688] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
90 Rico Montanari N, Anugwom CM, Boonstra A, Debes JD. The Role of Cytokines in the Different Stages of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4876. [PMID: 34638361 DOI: 10.3390/cancers13194876] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Witjes CD, van Aalten SM, Steyerberg EW, Borsboom GJ, de Man RA, Verhoef C, Ijzermans JN. Recently introduced biomarkers for screening of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatol Int. 2013;7:59-64. [PMID: 23519638 DOI: 10.1007/s12072-012-9374-3] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
92 Yang Y, Lin J, Guo S, Xue X, Wang Y, Qiu S, Cui J, Ma L, Zhang X, Wang J. RRM2 protects against ferroptosis and is a tumor biomarker for liver cancer. Cancer Cell Int 2020;20:587. [PMID: 33372599 DOI: 10.1186/s12935-020-01689-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
93 Bassyouni IH, Bassyouni RH, Ibrahim NH, Soliman AF. Elevated serum osteopontin levels in chronic hepatitis C virus infection: association with autoimmune rheumatologic manifestations. J Clin Immunol. 2012;32:1262-1269. [PMID: 22730056 DOI: 10.1007/s10875-012-9727-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
94 Zhao Y, Gao Q, Pei L, Wang C, Jin L, Liao F. Current Status and Future Prospects of Biomarkers in the Diagnosis of Hepatocellular Carcinoma. Int J Biol Markers 2017;32:361-9. [DOI: 10.5301/ijbm.5000299] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
95 Zhao M, Liang F, Zhang B, Yan W, Zhang J. The impact of osteopontin on prognosis and clinicopathology of colorectal cancer patients: a systematic meta-analysis. Sci Rep 2015;5:12713. [PMID: 26234583 DOI: 10.1038/srep12713] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
96 Yang G, Zhang S, Zhang Y, Zhou Q, Peng S, Zhang T, Yang C, Zhu Z, Zhang F. The inhibitory effects of extracellular ATP on the growth of nasopharyngeal carcinoma cells via P2Y2 receptor and osteopontin. J Exp Clin Cancer Res 2014;33:53. [PMID: 24961145 DOI: 10.1186/1756-9966-33-53] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
97 Wen Y, Jeong S, Xia Q, Kong X. Role of Osteopontin in Liver Diseases. Int J Biol Sci 2016;12:1121-8. [PMID: 27570486 DOI: 10.7150/ijbs.16445] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 6.2] [Reference Citation Analysis]
98 Nuñez-Garcia M, Gomez-Santos B, Buqué X, García-Rodriguez JL, Romero MR, Marin JJG, Arteta B, García-Monzón C, Castaño L, Syn WK, Fresnedo O, Aspichueta P. Osteopontin regulates the cross-talk between phosphatidylcholine and cholesterol metabolism in mouse liver. J Lipid Res 2017;58:1903-15. [PMID: 28754826 DOI: 10.1194/jlr.M078980] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
99 Qu L, Deng B, Zeng Y, Cao Z. Decreased expression of the Nkx2.8 gene correlates with tumor progression and a poor prognosis in HCC cancer. Cancer Cell Int 2014;14:28. [PMID: 24678995 DOI: 10.1186/1475-2867-14-28] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
100 Zhou JM, Wang T, Zhang KH. AFP-L3 for the diagnosis of early hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore) 2021;100:e27673. [PMID: 34713864 DOI: 10.1097/MD.0000000000027673] [Reference Citation Analysis]
101 Castello LM, Raineri D, Salmi L, Clemente N, Vaschetto R, Quaglia M, Garzaro M, Gentilli S, Navalesi P, Cantaluppi V, Dianzani U, Aspesi A, Chiocchetti A. Osteopontin at the Crossroads of Inflammation and Tumor Progression. Mediators Inflamm 2017;2017:4049098. [PMID: 28769537 DOI: 10.1155/2017/4049098] [Cited by in Crossref: 71] [Cited by in F6Publishing: 63] [Article Influence: 14.2] [Reference Citation Analysis]
102 De Stefano F, Chacon E, Turcios L, Marti F, Gedaly R. Novel biomarkers in hepatocellular carcinoma. Dig Liver Dis. 2018;50:1115-1123. [PMID: 30217732 DOI: 10.1016/j.dld.2018.08.019] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 8.5] [Reference Citation Analysis]
103 Goossens N, Bian CB, Hoshida Y. Tailored algorithms for hepatocellular carcinoma surveillance: Is one-size-fits-all strategy outdated? Curr Hepatol Rep 2017;16:64-71. [PMID: 28337405 DOI: 10.1007/s11901-017-0336-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
104 Chaiteerakij R, Addissie BD, Roberts LR. Update on biomarkers of hepatocellular carcinoma. Clin Gastroenterol Hepatol 2015;13:237-45. [PMID: 24275343 DOI: 10.1016/j.cgh.2013.10.038] [Cited by in Crossref: 72] [Cited by in F6Publishing: 72] [Article Influence: 8.0] [Reference Citation Analysis]
105 Fye HK, Wright-Drakesmith C, Kramer HB, Camey S, Nogueira da Costa A, Jeng A, Bah A, Kirk GD, Sharif MI, Ladep NG, Okeke E, Hainaut P, Taylor-Robinson SD, Kessler BM, Mendy ME. Protein profiling in hepatocellular carcinoma by label-free quantitative proteomics in two west African populations. PLoS One 2013;8:e68381. [PMID: 23935864 DOI: 10.1371/journal.pone.0068381] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
106 Lozada ME, Chaiteerakij R, Roberts LR. Screening for hepatocellular carcinoma and cholangiocarcinoma: Can biomarkers replace imaging? Curr Hepatol Rep 2015;14:128-38. [PMID: 26328266 DOI: 10.1007/s11901-015-0261-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
107 Douam F, Ploss A. Proteomic approaches to analyzing hepatitis C virus biology. Proteomics 2015;15:2051-65. [PMID: 25809442 DOI: 10.1002/pmic.201500009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
108 Wu H, Zhang H, Hu LY, Zhang TY, Zheng YJ, Shen F, Yang T. Is osteopontin a promising prognostic biomarker for cholangiocarcinoma? J Hepatol 2017:S0168-8278(17)32269-9. [PMID: 28870677 DOI: 10.1016/j.jhep.2017.08.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
109 Qin L. Osteopontin is a promoter for hepatocellular carcinoma metastasis: a summary of 10 years of studies. Front Med. 2014;8:24-32. [PMID: 24464486 DOI: 10.1007/s11684-014-0312-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
110 Liu Y, Zhang J, Chen Y, Sohel H, Ke X, Chen J, Li YX. The correlation and role analysis of COL4A1 and COL4A2 in hepatocarcinogenesis. Aging (Albany NY) 2020;12:204-23. [PMID: 31905170 DOI: 10.18632/aging.102610] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
111 Yilmaz Y, Ozturk O, Alahdab YO, Senates E, Colak Y, Doganay HL, Coskunpinar E, Oltulu YM, Eren F, Atug O, Tuncer I, Imeryuz N. Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease. Dig Liver Dis 2013;45:58-62. [PMID: 22995553 DOI: 10.1016/j.dld.2012.08.017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
112 Kaps L, Schuppan D. Targeting Cancer Associated Fibroblasts in Liver Fibrosis and Liver Cancer Using Nanocarriers. Cells 2020;9:E2027. [PMID: 32899119 DOI: 10.3390/cells9092027] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
113 Asgharpour A, Cazanave SC, Pacana T, Seneshaw M, Vincent R, Banini BA, Kumar DP, Daita K, Min HK, Mirshahi F. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. J Hepatol. 2016;65:579-588. [PMID: 27261415 DOI: 10.1016/j.jhep.2016.05.005] [Cited by in Crossref: 198] [Cited by in F6Publishing: 187] [Article Influence: 33.0] [Reference Citation Analysis]
114 Sulpice L, Rayar M, Desille M, Turlin B, Fautrel A, Boucher E, Llamas-Gutierrez F, Meunier B, Boudjema K, Clément B. Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma. Hepatology. 2013;58:1992-2000. [PMID: 23775819 DOI: 10.1002/hep.26577] [Cited by in Crossref: 77] [Cited by in F6Publishing: 125] [Article Influence: 8.6] [Reference Citation Analysis]
115 Cao DX, Li ZJ, Jiang XO, Lum YL, Khin E, Lee NP, Wu GH, Luk JM. Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers. World J Gastroenterol 2012; 18(30): 3923-3930 [PMID: 22912540 DOI: 10.3748/wjg.v18.i30.3923] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 54] [Article Influence: 5.4] [Reference Citation Analysis]
116 Khalil A, Elgedawy J, Faramawi MF, Elfert A, Salama I, Abbass A, Elsaid H, Elsebaai H. Plasma Osteopontin Level as a Diagnostic Marker of Hepatocellular Carcinoma in Patients with Radiological Evidence of Focal Hepatic Lesions. Tumori 2013;99:100-7. [DOI: 10.1177/030089161309900117] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
117 Faltermeier C, Busuttil RW, Zarrinpar A. A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. Diseases 2015;3:221-52. [PMID: 28943622 DOI: 10.3390/diseases3040221] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
118 Xing X, Liang D, Huang Y, Zeng Y, Han X, Liu X, Liu J. The application of proteomics in different aspects of hepatocellular carcinoma research. Journal of Proteomics 2016;145:70-80. [DOI: 10.1016/j.jprot.2016.03.050] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
119 Naryzhny S, Zgoda V, Kopylov A, Petrenko E, Kleist O, Archakov А. Variety and Dynamics of Proteoforms in the Human Proteome: Aspects of Markers for Hepatocellular Carcinoma. Proteomes 2017;5:E33. [PMID: 29168748 DOI: 10.3390/proteomes5040033] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
120 Zhang Y, Gao J, Bao Y, Liu Y, Tong Y, Jin S, Zhao Q. Diagnostic accuracy and prognostic significance of osteopontin in liver cirrhosis and hepatocellular carcinoma: a Meta-analysis. Biomarkers 2021;:1-9. [PMID: 34787036 DOI: 10.1080/1354750X.2021.2008009] [Reference Citation Analysis]
121 Jin H, Zhang Y, You H, Tao X, Wang C, Jin G, Wang N, Ruan H, Gu D, Huo X, Cong W, Qin W. Prognostic significance of kynurenine 3-monooxygenase and effects on proliferation, migration, and invasion of human hepatocellular carcinoma. Sci Rep 2015;5:10466. [PMID: 26099564 DOI: 10.1038/srep10466] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 4.7] [Reference Citation Analysis]
122 Fitian AI, Cabrera R. Disease monitoring of hepatocellular carcinoma through metabolomics. World J Hepatol 2017; 9(1): 1-17 [PMID: 28105254 DOI: 10.4254/wjh.v9.i1.1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
123 Kang YS, Jeong EJ, Seok HJ, Kim SK, Hwang JS, Choi ML, Jo DG, Kim Y, Choi J, Lee YJ, Jung E, Min JK, Han TS, Kim JS. Cks1 regulates human hepatocellular carcinoma cell progression through osteopontin expression. Biochem Biophys Res Commun 2019;508:275-81. [PMID: 30497779 DOI: 10.1016/j.bbrc.2018.11.070] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
124 Nambotin SB, Tomimaru Y, Merle P, Wands JR, Kim M. Functional consequences of WNT3/Frizzled7-mediated signaling in non-transformed hepatic cells. Oncogenesis 2012;1:e31. [PMID: 23552403 DOI: 10.1038/oncsis.2012.31] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
125 Gonzalez SA. Novel biomarkers for hepatocellular carcinoma surveillance: has the future arrived? Hepatobiliary Surg Nutr. 2014;3:410-414. [PMID: 25568864 DOI: 10.3978/j.issn.2304-3881.2014.07.06] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
126 Bruha R, Jachymova M, Petrtyl J, Dvorak K, Lenicek M, Urbanek P, Svestka T, Vitek L. Osteopontin: A non-invasive parameter of portal hypertension and prognostic marker of cirrhosis. World J Gastroenterol 2016; 22(12): 3441-3450 [PMID: 27022226 DOI: 10.3748/wjg.v22.i12.3441] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
127 Cao Y, Chen D, Chen W, Yu J, Chen Z, Li G. Aptamer-based homogeneous protein detection using cucurbit[7]uril functionalized electrode. Anal Chim Acta 2014;812:45-9. [PMID: 24491763 DOI: 10.1016/j.aca.2014.01.008] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 4.6] [Reference Citation Analysis]
128 Long J, Chen P, Lin J, Bai Y, Yang X, Bian J, Lin Y, Wang D, Yang X, Zheng Y, Sang X, Zhao H. DNA methylation-driven genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma. Theranostics. 2019;9:7251-7267. [PMID: 31695766 DOI: 10.7150/thno.31155] [Cited by in Crossref: 17] [Cited by in F6Publishing: 26] [Article Influence: 5.7] [Reference Citation Analysis]
129 Xu Y, Rong J, Duan S, Chen C, Li Y, Peng B, Yi B, Zheng Z, Gao Y, Wang K, Yun M, Weng H, Zhang J, Ye S. High expression of GNA13 is associated with poor prognosis in hepatocellular carcinoma. Sci Rep 2016;6:35948. [PMID: 27883022 DOI: 10.1038/srep35948] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
130 Parikh ND, Mehta AS, Singal AG, Block T, Marrero JA, Lok AS. Biomarkers for the Early Detection of Hepatocellular Carcinoma.Cancer Epidemiol Biomarkers Prev. 2020;29:2495-2503. [PMID: 32238405 DOI: 10.1158/1055-9965.EPI-20-0005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
131 Colli A, Nadarevic T, Miletic D, Giljaca V, Fraquelli M, Štimac D, Casazza G. Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2021;4:CD013346. [PMID: 33855699 DOI: 10.1002/14651858.CD013346.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
132 Srungaram P, Rule JA, Yuan HJ, Reimold A, Dahl B, Sanders C, Lee WM. Plasma osteopontin in acute liver failure. Cytokine. 2015;73:270-276. [PMID: 25802196 DOI: 10.1016/j.cyto.2015.02.021] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
133 Kawai T, Yasuchika K, Ishii T, Miyauchi Y, Kojima H, Yamaoka R, Katayama H, Yoshitoshi EY, Ogiso S, Kita S, Yasuda K, Fukumitsu K, Komori J, Hatano E, Kawaguchi Y, Uemoto S. SOX9 is a novel cancer stem cell marker surrogated by osteopontin in human hepatocellular carcinoma. Sci Rep. 2016;6:30489. [PMID: 27457505 DOI: 10.1038/srep30489] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 7.2] [Reference Citation Analysis]
134 Song P, Tang Q, Feng X, Tang W. Biomarkers: evaluation of clinical utility in surveillance and early diagnosis for hepatocellular carcinoma. Scand J Clin Lab Invest Suppl 2016;245:S70-6. [PMID: 27438343 DOI: 10.1080/00365513.2016.1210328] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
135 Ma W, Hong Z, Liu H, Chen X, Ding L, Liu Z, Zhou F, Yuan Y. Human Endogenous Retroviruses-K (HML-2) Expression Is Correlated with Prognosis and Progress of Hepatocellular Carcinoma. Biomed Res Int 2016;2016:8201642. [PMID: 28070518 DOI: 10.1155/2016/8201642] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
136 Cabiati M, Gaggini M, Cesare MM, Caselli C, De Simone P, Filipponi F, Basta G, Gastaldelli A, Del Ry S. Osteopontin in hepatocellular carcinoma: A possible biomarker for diagnosis and follow-up. Cytokine 2017;99:59-65. [PMID: 28711012 DOI: 10.1016/j.cyto.2017.07.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
137 Ahmed Mohammed HF, Roberts LR. Should AFP (or any biomarkers) be used for HCC surveillance? Curr Hepatol Rep 2017;16:137-45. [PMID: 29085770 DOI: 10.1007/s11901-017-0349-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
138 Pandyarajan V, Govalan R, Yang JD. Risk Factors and Biomarkers for Chronic Hepatitis B Associated Hepatocellular Carcinoma. Int J Mol Sci 2021;22:E479. [PMID: 33418899 DOI: 10.3390/ijms22020479] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
139 Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589-604. [PMID: 31439937 DOI: 10.1038/s41575-019-0186-y] [Cited by in Crossref: 690] [Cited by in F6Publishing: 718] [Article Influence: 230.0] [Reference Citation Analysis]
140 Nagoshi S. Osteopontin: Versatile modulator of liver diseases. Hepatol Res. 2014;44:22-30. [PMID: 23701387 DOI: 10.1111/hepr.12166] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 6.2] [Reference Citation Analysis]
141 Osna NA, Ganesan M, Seth D, Wyatt TA, Kidambi S, Kharbanda KK. Second hits exacerbate alcohol-related organ damage: an update. Alcohol Alcohol 2021;56:8-16. [PMID: 32869059 DOI: 10.1093/alcalc/agaa085] [Reference Citation Analysis]
142 Feng Z, Marrero JA, Khaderi S, Singal AG, Kanwal F, Loo N, Beretta L, Ning J, El-Serag HB. Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study. Am J Gastroenterol 2019;114:530-2. [PMID: 30699099 DOI: 10.14309/ajg.0000000000000068] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
143 Huang F, Cai P, Wang Y, Zhou X, Chen H, Liao W, Mao Y, Zha X, Zhang H, Hu Z. Up-regulation of brain-expressed X-linked 2 is critical for hepatitis B virus X protein-induced hepatocellular carcinoma development. Oncotarget 2017;8:65789-99. [PMID: 29029472 DOI: 10.18632/oncotarget.19477] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
144 Zhao R, Li T, Zheng G, Jiang K, Fan L, Shao J. Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex. Biomaterials 2017;143:1-16. [DOI: 10.1016/j.biomaterials.2017.07.030] [Cited by in Crossref: 86] [Cited by in F6Publishing: 77] [Article Influence: 17.2] [Reference Citation Analysis]
145 Knudsen ES, Gopal P, Singal AG. The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy. Am J Pathol. 2014;184:574-583. [PMID: 24388934 DOI: 10.1016/j.ajpath.2013.10.028] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 6.1] [Reference Citation Analysis]
146 Sun T, Tang Y, Sun D, Bu Q, Li P. Osteopontin versus alpha-fetoprotein as a diagnostic marker for hepatocellular carcinoma: a meta-analysis. Onco Targets Ther 2018;11:8925-35. [PMID: 30573979 DOI: 10.2147/OTT.S186230] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
147 Mehta A, Herrera H, Block T. Glycosylation and liver cancer. Adv Cancer Res. 2015;126:257-279. [PMID: 25727150 DOI: 10.1016/bs.acr.2014.11.005] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 9.0] [Reference Citation Analysis]
148 Della Corte C, Colombo M. Surveillance for hepatocellular carcinoma. Semin Oncol. 2012;39:384-398. [PMID: 22846857 DOI: 10.1053/j.seminoncol.2012.05.002] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 3.9] [Reference Citation Analysis]
149 Li T, Li H, Wang A, Su X, Zhao J, Cui Y, Liu J, Hu J. Development And Validation Of A Simple Model For Detection Of Early Hepatocellular Carcinoma In A Liver Cirrhosis Cohort. Cancer Manag Res 2019;11:9379-86. [PMID: 31807067 DOI: 10.2147/CMAR.S221050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
150 Fu CL, Pan B, Pan JH, Gan MF. Metallothionein 1M suppresses tumorigenesis in hepatocellular carcinoma. Oncotarget 2017;8:33037-46. [PMID: 28380433 DOI: 10.18632/oncotarget.16521] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
151 Rong W, Zhang Y, Yang L, Feng L, Wei B, Wu F, Wang L, Gao Y, Cheng S, Wu J, Xiao T. Post-surgical resection prognostic value of combined OPN, MMP7, and PSG9 plasma biomarkers in hepatocellular carcinoma. Front Med 2019;13:250-8. [PMID: 29770948 DOI: 10.1007/s11684-018-0632-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
152 Zhang J, Jiao J, Cermelli S, Muir K, Jung KH, Zou R, Rashid A, Gagea M, Zabludoff S, Kalluri R, Beretta L. miR-21 Inhibition Reduces Liver Fibrosis and Prevents Tumor Development by Inducing Apoptosis of CD24+ Progenitor Cells. Cancer Res. 2015;75:1859-1867. [PMID: 25769721 DOI: 10.1158/0008-5472.can-14-1254] [Cited by in Crossref: 59] [Cited by in F6Publishing: 34] [Article Influence: 8.4] [Reference Citation Analysis]
153 Kim DY, Han KH. Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer 2012;1:2-14. [PMID: 24159567 DOI: 10.1159/000339016] [Cited by in Crossref: 73] [Cited by in F6Publishing: 74] [Article Influence: 9.1] [Reference Citation Analysis]
154 Simão A, Madaleno J, Silva N, Rodrigues F, Caseiro P, Costa JN, Carvalho A. Plasma osteopontin is a biomarker for the severity of alcoholic liver cirrhosis, not for hepatocellular carcinoma screening. BMC Gastroenterol 2015;15:73. [PMID: 26122937 DOI: 10.1186/s12876-015-0307-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
155 Zhou Y, Romson J, Emmer Å. An antibody-free sample pretreatment method for osteopontin combined with MALDI-TOF MS/MS analysis. PLoS One 2019;14:e0213405. [PMID: 30845167 DOI: 10.1371/journal.pone.0213405] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
156 Pereira TA, Syn WK, Machado MV, Vidigal PV, Resende V, Voieta I, Xie G, Otoni A, Souza MM, Santos ET. Schistosome-induced cholangiocyte proliferation and osteopontin secretion correlate with fibrosis and portal hypertension in human and murine schistosomiasis mansoni. Clin Sci (Lond). 2015;129:875-883. [PMID: 26201095 DOI: 10.1042/cs20150117] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
157 Mattos ÂZ, Debes JD, Boonstra A, Vogel A, Mattos AA. Immune aspects of hepatocellular carcinoma: From immune markers for early detection to immunotherapy. World J Gastrointest Oncol 2021; 13(9): 1132-1143 [PMID: 34616518 DOI: 10.4251/wjgo.v13.i9.1132] [Reference Citation Analysis]
158 Belczacka I, Latosinska A, Metzger J, Marx D, Vlahou A, Mischak H, Frantzi M. Proteomics biomarkers for solid tumors: Current status and future prospects. Mass Spectrom Rev 2019;38:49-78. [PMID: 29889308 DOI: 10.1002/mas.21572] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
159 Zhou C, Zhou HJ, Zhang XF, Lou LL, Ye QH, Zheng Y, Wang J, Zhu HT, Dong QZ, Jia HL, Zhu WW, Guo L, Zhao Y, Gao DM, Qin LX. Postoperative serum osteopontin level is a novel monitor for treatment response and tumor recurrence after resection of hepatitis B-related hepatocellular carcinoma. Ann Surg Oncol 2013;20:929-37. [PMID: 23203407 DOI: 10.1245/s10434-012-2749-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
160 Li JJ, Li HY, Gu F. Diagnostic significance of serum osteopontin level for pancreatic cancer: a meta-analysis. Genet Test Mol Biomarkers. 2014;18:580-586. [PMID: 24950303 DOI: 10.1089/gtmb.2014.0102] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
161 Khan IM, Gjuka D, Jiao J, Song X, Wang Y, Wang J, Wei P, El-Serag HB, Marrero JA, Beretta L. A Novel Biomarker Panel for the Early Detection and Risk Assessment of Hepatocellular Carcinoma in Patients with Cirrhosis. Cancer Prev Res (Phila) 2021;14:667-74. [PMID: 33685927 DOI: 10.1158/1940-6207.CAPR-20-0600] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
162 Lu C, Fang S, Weng Q, Lv X, Meng M, Zhu J, Zheng L, Hu Y, Gao Y, Wu X, Mao J, Tang B, Zhao Z, Huang L, Ji J. Integrated analysis reveals critical glycolytic regulators in hepatocellular carcinoma. Cell Commun Signal 2020;18:97. [PMID: 32576292 DOI: 10.1186/s12964-020-00539-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
163 Dong QZ, Zhang XF, Zhao Y, Jia HL, Zhou HJ, Dai C, Sun HJ, Qin Y, Zhang WD, Ren N. Osteopontin promoter polymorphisms at locus -443 significantly affect the metastasis and prognosis of human hepatocellular carcinoma. Hepatology. 2013;57:1024-1034. [PMID: 23079960 DOI: 10.1002/hep.26103] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
164 Fukuda T, Sanui T, Toyoda K, Tanaka U, Taketomi T, Uchiumi T, Nishimura F. Identification of novel amelogenin-binding proteins by proteomics analysis. PLoS One 2013;8:e78129. [PMID: 24167599 DOI: 10.1371/journal.pone.0078129] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
165 Francica G, Borzio M. Status of, and strategies for improving, adherence to HCC screening and surveillance. J Hepatocell Carcinoma 2019;6:131-41. [PMID: 31440486 DOI: 10.2147/JHC.S159269] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
166 Simpson HN, McGuire BM. Screening and detection of hepatocellular carcinoma. Clin Liver Dis 2015;19:295-307. [PMID: 25921664 DOI: 10.1016/j.cld.2015.01.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
167 Lee YS, Ko E, Yoon EL, Jung YK, Kim JH, Seo YS, Yim HJ, Kim KH, Kwon SY, Yeon JE, Um SH, Byun KS. Multiplexed Proteomic Approach for Identification of Serum Biomarkers in Hepatocellular Carcinoma Patients with Normal AFP. J Clin Med 2020;9:E323. [PMID: 31979338 DOI: 10.3390/jcm9020323] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
168 Wang T, Zhang KH. New Blood Biomarkers for the Diagnosis of AFP-Negative Hepatocellular Carcinoma. Front Oncol 2020;10:1316. [PMID: 32923383 DOI: 10.3389/fonc.2020.01316] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
169 Zhang J, Chen G, Zhang P, Zhang J, Li X, Gan D, Cao X, Han M, Du H, Ye Y. The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. PLoS One. 2020;15:e0228857. [PMID: 32053643 DOI: 10.1371/journal.pone.0228857] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 10.5] [Reference Citation Analysis]
170 Delacourt AT, Mehta AS. Liver Cancer (Current Therapies). Reference Module in Biomedical Sciences. Elsevier; 2021. [DOI: 10.1016/b978-0-12-820472-6.00007-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
171 Shalably NM, Badawi R, Hawash N, Abd-elsalam S, Elkhalawany W, Hameed AAE, Alkassas GE. Evaluation of Fucosylated Haptoglobin as a Diagnostic Biomarker for Hepatocellular Carcinoma in Egypt. TOBIOMJ 2019;9:31-7. [DOI: 10.2174/1875318301909010031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
172 Moorman HR, Poschel D, Klement JD, Lu C, Redd PS, Liu K. Osteopontin: A Key Regulator of Tumor Progression and Immunomodulation. Cancers (Basel) 2020;12:E3379. [PMID: 33203146 DOI: 10.3390/cancers12113379] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
173 Jang ES, Jeong SH, Kim JW, Choi YS, Leissner P, Brechot C. Diagnostic Performance of Alpha-Fetoprotein, Protein Induced by Vitamin K Absence, Osteopontin, Dickkopf-1 and Its Combinations for Hepatocellular Carcinoma. PLoS One. 2016;11:e0151069. [PMID: 26986465 DOI: 10.1371/journal.pone.0151069] [Cited by in Crossref: 40] [Cited by in F6Publishing: 46] [Article Influence: 6.7] [Reference Citation Analysis]
174 Attallah A, Albannan M, El-deen M, Farid K, Khedr F, Attallah K, Abdallah S. Diagnostic role of collagen-III and matrix metalloproteinase-1 for early detection of hepatocellular carcinoma. British Journal of Biomedical Science 2020;77:58-63. [DOI: 10.1080/09674845.2019.1708534] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
175 Lou J, Zhang L, Lv S, Zhang C, Jiang S. Biomarkers for Hepatocellular Carcinoma. Biomark Cancer. 2017;9:1-9. [PMID: 28469485 DOI: 10.1177/1179299x16684640] [Cited by in Crossref: 61] [Cited by in F6Publishing: 41] [Article Influence: 12.2] [Reference Citation Analysis]
176 Zhang M, Zhao W, Liu S, Liu H, Liu L, Peng Q, Du C, Jiang N. H/ACA snoRNP Gene Family as Diagnostic and Prognostic Biomarkers for Hepatocellular Carcinoma. Pharmgenomics Pers Med 2021;14:1331-45. [PMID: 34703278 DOI: 10.2147/PGPM.S333838] [Reference Citation Analysis]
177 Mischak H, Critselis E, Hanash S, Gallagher WM, Vlahou A, Ioannidis JP. Epidemiologic design and analysis for proteomic studies: a primer on -omic technologies. Am J Epidemiol. 2015;181:635-647. [PMID: 25792606 DOI: 10.1093/aje/kwu462] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
178 Huang Z, Ma L, Huang C, Li Q, Nice EC. Proteomic profiling of human plasma for cancer biomarker discovery. Proteomics 2017;17:1600240. [DOI: 10.1002/pmic.201600240] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
179 Kim JU, Shariff MIF, Crossey MME, Gomez-Romero M, Holmes E, Cox IJ, Fye HKS, Njie R, Taylor-Robinson SD. Hepatocellular carcinoma: Review of disease and tumor biomarkers. World J Hepatol 2016; 8(10): 471-484 [PMID: 27057305 DOI: 10.4254/wjh.v8.i10.471] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
180 Ge T, Shen Q, Wang N, Zhang Y, Ge Z, Chu W, Lv X, Zhao F, Zhao W, Fan J, Qin W. Diagnostic values of alpha-fetoprotein, dickkopf-1, and osteopontin for hepatocellular carcinoma. Med Oncol 2015;32. [DOI: 10.1007/s12032-014-0367-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
181 Petrizzo A, Buonaguro L. Application of the Immunoscore as prognostic tool for hepatocellular carcinoma. J Immunother Cancer. 2016;4:71. [PMID: 27879973 DOI: 10.1186/s40425-016-0182-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
182 El-Khazragy N, Khalifa MM, Salem AM, Swellam M, Hegazy M. Evaluation of Osteopontin and Pokémon genes expression in hepatitis C virus-associated hepatocellular carcinoma. J Cell Biochem 2018. [PMID: 30417409 DOI: 10.1002/jcb.28018] [Reference Citation Analysis]
183 Li D, Satomura S. Biomarkers for Hepatocellular Carcinoma (HCC): An Update. Adv Exp Med Biol 2015;867:179-93. [PMID: 26530367 DOI: 10.1007/978-94-017-7215-0_12] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
184 Kim KH, Lee SY, Hwang H, Lee JY, Ji ES, An HJ, Kim JY, Yoo JS. Direct Monitoring of Fucosylated Glycopeptides of Alpha-Fetoprotein in Human Serum for Early Hepatocellular Carcinoma by Liquid Chromatography-Tandem Mass Spectrometry with Immunoprecipitation. Proteomics Clin Appl 2018;12:e1800062. [PMID: 29888876 DOI: 10.1002/prca.201800062] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
185 McQuitty CE, Williams R, Chokshi S, Urbani L. Immunomodulatory Role of the Extracellular Matrix Within the Liver Disease Microenvironment. Front Immunol 2020;11:574276. [PMID: 33262757 DOI: 10.3389/fimmu.2020.574276] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
186 Beudeker BJB, Boonstra A. Circulating biomarkers for early detection of hepatocellular carcinoma. Therap Adv Gastroenterol 2020;13:1756284820931734. [PMID: 32647536 DOI: 10.1177/1756284820931734] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
187 Byron A, Humphries JD, Humphries MJ. Defining the extracellular matrix using proteomics. Int J Exp Pathol 2013;94:75-92. [PMID: 23419153 DOI: 10.1111/iep.12011] [Cited by in Crossref: 92] [Cited by in F6Publishing: 87] [Article Influence: 10.2] [Reference Citation Analysis]
188 Yang P, Markowitz GJ, Wang XF. The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma. Natl Sci Rev 2014;1:396-412. [PMID: 25741453 DOI: 10.1093/nsr/nwu038] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]